Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Terese Hylander; Olivia Larsson; Ulla Westin; Mia Eriksson; Susanna Kumlien Georén; Ola Winqvist; Lars-Olaf Cardell

doi:10.1186/s12931-016-0324-9

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Terese Hylander, Olivia Larsson, Ulla Westin, Mia Eriksson, Susanna Kumlien Georén, Ola Winqvist, Lars-Olaf Cardell

Research output: Contribution to journal › Article › peer-review

Abstract

Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.

Original language	English
Article number	10
Journal	Respiratory Research
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s12931-016-0324-9
Publication status	Published - 2016

Subject classification (UKÄ)

Respiratory Medicine and Allergy

Access to Document

10.1186/s12931-016-0324-9

http://www.ncbi.nlm.nih.gov/pubmed/26817454?dopt=Abstract

Cite this

@article{0c8f37cb727b4bf09aa0769d3469fdcc,

title = "Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.",

abstract = "Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.",

author = "Terese Hylander and Olivia Larsson and Ulla Westin and Mia Eriksson and \{Kumlien Geor{\'e}n\}, Susanna and Ola Winqvist and Lars-Olaf Cardell",

year = "2016",

doi = "10.1186/s12931-016-0324-9",

language = "English",

volume = "17",

journal = "Respiratory Research",

issn = "1465-9921",

publisher = "BioMed Central (BMC)",

number = "1",

}

TY - JOUR

T1 - Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

AU - Hylander, Terese

AU - Larsson, Olivia

AU - Westin, Ulla

AU - Eriksson, Mia

AU - Kumlien Georén, Susanna

AU - Winqvist, Ola

AU - Cardell, Lars-Olaf

PY - 2016

Y1 - 2016

N2 - Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.

AB - Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.

UR - https://www.scopus.com/pages/publications/84956586407

U2 - 10.1186/s12931-016-0324-9

DO - 10.1186/s12931-016-0324-9

M3 - Article

C2 - 26817454

SN - 1465-9921

VL - 17

JO - Respiratory Research

JF - Respiratory Research

IS - 1

M1 - 10

ER -

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Abstract

Subject classification (UKÄ)

Access to Document

Other files and links

Fingerprint

Cite this